Last reviewed · How we verify
Treatment with hP1A8 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Treatment with hP1A8 (Treatment with hP1A8) — OX2 Therapeutics.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Treatment with hP1A8 TARGET | Treatment with hP1A8 | OX2 Therapeutics | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Treatment with hP1A8 CI watch — RSS
- Treatment with hP1A8 CI watch — Atom
- Treatment with hP1A8 CI watch — JSON
- Treatment with hP1A8 alone — RSS
Cite this brief
Drug Landscape (2026). Treatment with hP1A8 — Competitive Intelligence Brief. https://druglandscape.com/ci/treatment-with-hp1a8. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab